Nine research projects at Rice University have been granted $25,000 to advance their innovative solutions. Photo courtesy of Rice

Over a dozen Houston researchers wrapped up 2021 with the news of fresh funding thanks to an initiative and investment fund from Rice University.

The Technology Development Fund is a part of the university’s Creative Ventures initiative, which has awarded more than $4 million in grants since its inception in 2016. Rice's Office of Technology Transfer orchestrated the $25,000 grants across nine projects. Submissions were accepted through October and the winners were announced a few weeks ago.

The 2021 winners, according to Rice's news release, were:

  • Kevin McHugh, an assistant professor of bioengineering, is working on a method to automate an encapsulation process that uses biodegradable microparticles in the timed release of drugs to treat cancer and prevent infectious disease. He suggested the process could help ramp up the manufacture of accessible multidose vaccines.
  • Daniel Preston, an assistant professor of mechanical engineering, is developing a novel filtration system that will recover water typically released by cooling towers at natural gas power plants. The inexpensive filters will result in a significant savings in water costs during power generation.
  • Geoff Wehmeyer, an assistant professor of mechanical engineering; Matteo Pasquali, the A.J. Hartsook Professor of Chemical and Biomolecular Engineering and a professor of chemistry and materials science and nanoengineering; Junichiro Kono, the Karl F. Hasselmann Chair in Engineering, a professor of electrical and computer engineering, physics and astronomy and materials science and nanoengineering and chair of the applied physics program, and Glen Irvin Jr., a research professor in chemical and biomolecular engineering, are creating a solid-state, active heat-switching device to enable the rapid charging of batteries for electric vehicles. The lightweight device will use carbon nanotube fibers to optimize battery thermal management systems not only for cars but also, eventually, for electronic devices like laptops.
  • Xia Ben Hu, an associate professor of computer science, is developing his open-source machine learning system to democratize and accelerate small businesses’ digital transformation in e-commerce.
  • Bruce Weisman, a professor of chemistry and of materials science and nanoengineering, and Satish Nagarajaiah, a professor of civil and environmental engineering and of mechanical engineering, are working to advance their strain measurement system based on the spectral properties of carbon nanotubes. The system will allow for quick measurement of strain to prevent catastrophic failures and ensure the safety of aircraft, bridges, buildings, pipelines, ships, chemical storage vessels and other infrastructure.
  • Aditya Mohite, a professor of chemical and biomolecular engineering and associate professor of materials science and nanoengineering, and Michael Wong, the Tina and Sunit Patel Professor in Molecular Nanotechnology, a professor and chair of chemical and biomolecular engineering and a professor of chemistry, materials science and nanoengineering and of civil and environmental engineering, are scaling up novel photoreactors for the environmentally friendly generation of hydrogen. Their process combines of perovskite-based solar cells and state-of-the-art catalysts.
  • Rebekah Drezek, a professor of bioengineering, and Richard Baraniuk, the C. Sidney Burrus Professor of Electrical and Computer Engineering and a professor of statistics and computer science, are developing a system to rapidly diagnose sepsis using microfluidics and compressed sensing to speed the capture and analysis of microbial biomarkers.
  • Fathi Ghorbel, a professor of mechanical engineering and of bioengineering, is working on robotic localization technology in GPS-denied environments such as aboveground storage tanks, pressure vessels and floating production storage and offloading tanks. The system would enable robots to precisely associate inspection data to specific locations leading to efficiency and high quality of inspection and maintenance operations where regular inspections are required. This will dramatically improve the environmental impact and safety of these assets.
  • Kai Fu, a research scientist, and Yuji Zhao, an associate professor of electrical and computer engineering, are working to commercialize novel power diodes and transistors for electric vehicles. They expect their devices to reduce the volume of power systems while improving integration, power density, heat dissipation, storage, and energy efficiency.
Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston researchers report promising first in-human trial for implantable cancer therapy

cancer breakthrough

When it comes to cancer remedies, the treatment can be as challenging for the body as its cause. But what if immunotherapy could be localized? That’s precisely what a Houston team may soon make a reality.

Rice University researchers, in partnership with MD Anderson Cancer Center, recently published their findings from the first in-human trial of an implantable cancer-fighting treatment in the journal Clinical Cancer Research. The paper details testing of AVB-001, encapsulated cells engineered to release interleukin-2 (IL-2)—a naturally occurring signaling protein that boosts immunity—in the peritoneal cavities of 14 patients. The goal is to avoid the toxicity usually experienced with less targeted treatments, as well as find a solution to IL-2s’ abbreviated half-lives.

“Traditional IL-2 therapy has shown potent antitumor activity, but its clinical use has been limited by severe side effects and delivery challenges,” Omid Veiseh, director of the Rice Biotech Launch Pad, professor of bioengineering at Rice and a senior author on the study, said in a press release. “This platform allows us to localize and sustain cytokine exposure directly where tumors reside while minimizing systemic toxicity.”

Serous ovarian carcinoma is especially well-suited to the use of AVB-001 because it tends to spread throughout the abdomen. After a minimally invasive laparoscopic procedure, patients implanted with the cells were noted to tolerate the treatment well. Half of the enrolled patients’ cancer was stabilized, with several among them reporting extended signs of benefit. No maximum tolerated dose was reached and there were no life-threatening events tied to the study.

If that sounds like less-than-earth-shaking results, this is only the beginning. The capsules were implanted for about one week because IL-2 activity drops off after that. The researchers now know that further testing should include either higher levels, repeated doses, or a combination thereof, in order to create stronger advances.

The team has already made early headway on this next step. Preclinical studies in nonhuman primates were not only tolerated well, but without added toxicity, the apes had consistent pharmacological effects.

“This is a foundational step,” Veiseh explained. “We now have evidence that the platform is safe, biologically active and potentially scalable. The next phase is optimizing dosing and exploring combination therapies to unlock its full clinical potential.”

The combination would also include a checkpoint inhibitor, which might improve AVB-001’s tumor-fighting power. “What is exciting is that we are not just delivering a drug, we are programming a microenvironment,” added Dr. Amir Jazaeri, professor of gynecologic oncology at MD Anderson, member of the Rice Biotech Launch Pad’s clinical advisory board and a senior author on the study. “This opens the door to combination strategies that could amplify immune responses in ways that have not been feasible before.”

Houston startup raises $6M to scale home-based healthcare platform

fresh funding

As healthcare systems race to expand care beyond hospitals and into the home, investors are placing bigger bets on the infrastructure needed to make that shift possible.

This month, Rosarium Health announced it has raised $6 million in seed funding led by Kalos Ventures, with participation from ResilienceVC, Rock Health Capital, Symphonic Capital, Black Tech Nations Ventures and others.

The investment will help the Houston-based startup continue to build its platform, which features a national network of 800-plus clinicians and 3,000-plus contractors to coordinate home accessibility upgrades and modifications for seniors and people living with disabilities.

For founder and CEO Cameron Carter, the company’s mission grew out of firsthand caregiving experiences.

“From my own personal caregiving experiences, I realized that the benefits exist on paper, but not in reality,” Carter said in a news release. “Families are being left to figure out the paperwork and installations all on their own, which shouldn’t be how this works.”

While Medicare Advantage and Medicaid plans have expanded coverage for home-based services and accessibility modifications, the logistics behind delivering those services often remain fragmented.

Rosarium’s platform coordinates the entire process, from clinical assessments and referrals to contractor management, documentation, reimbursement and installation.

“A clinician can document that a home isn’t safe and a plan can approve a benefit, but there’s no one that’s responsible for making sure the work actually gets done,” Carter says. “We built the missing piece.”

The company was founded in 2021 as Rose Health and was a 2023 participant in the Texas Medical Center’s Accelerator for HealthTech program. It has scaled quickly, building a network of more than 800 clinicians and 3,000 contractors across 34 states.

Rosarium is currently in-network for 1.2 million Medicare and Medicaid lives, with projected coverage expected to reach nearly 4 million by the end of the year, according to the release.

“We’re excited to back Cameron because he and the team at Rosarium are building the infrastructure healthcare needs right now to make the home a safe and comfortable place of care,” Kate Ballinger, investor at Kalos Ventures, added in the release.

As part of the recent investment, Ballinger will join Rosarium’s board of directors.

With eyes on the future, Rosarium plans to grow its partnerships with Medicaid and Medicare Advantage plans, including CalViva and Community Health Plan of Imperial Valley, strengthening its presence in California while expanding access to underserved communities.

Additionally, Carter predicts that home-based healthcare will be part of a broader transformation happening across the industry.

“There’s a growing recognition that health outcomes are shaped by what happens in the home,” he said in the release. “The future of healthcare isn’t just treating people after something goes wrong. It’s creating environments that help prevent those problems in the first place.”